이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Venus Medtech (Hangzhou) 관리

관리 기준 확인 1/4

Venus Medtech (Hangzhou)'s CEO는 Lin Haosheng Lim, Dec2016 에 임명되었습니다 의 임기는 7.17 년입니다. 총 연간 보상은 CN¥ 1.26M, 85.4% 로 구성됩니다. 85.4% 급여 및 14.6% 보너스(회사 주식 및 옵션 포함). 는 HK$ 17.67M 가치에 해당하는 회사 주식의 0.72% 직접 소유합니다. 17.67M. 경영진과 이사회의 평균 재임 기간은 각각 1.9 년과 2.9 년입니다.

주요 정보

Lin Haosheng Lim

최고 경영자

CN¥1.3m

총 보상

CEO 급여 비율	85.4%
CEO 임기	7.2yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08

CEO 보상 분석

Lin Haosheng Lim 의 보수는 Venus Medtech (Hangzhou) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥1m	CN¥1m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥759m
Jun 30 2022	n/a	n/a	-CN¥461m
Mar 31 2022	n/a	n/a	-CN¥417m
Dec 31 2021	CN¥1m	CN¥694k	-CN¥374m

보상 대 시장: Lin Haosheng 의 총 보상 ($USD 175.50K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 358.97K ).

보상과 수익: 회사가 수익성이 없는 동안 Lin Haosheng 의 보상이 증가했습니다.

CEO

Lin Haosheng Lim (49 yo)

7.2yrs

테뉴어

CN¥1,263,000

보상

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hou-Sen Lim	GM, COO & CTO	7.2yrs	CN¥1.26m	0.72% CN¥ 17.7m
Fei Wang	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Joyce Heo	Director of Sales	1.9yrs	데이터 없음	데이터 없음
Christopher Richardson	Head of U.S. Operations	4.6yrs	데이터 없음	데이터 없음
Amir Gross	Head of Venus Global Heart Valve Innovation Center	1.9yrs	데이터 없음	데이터 없음
Shakeel Osman	Senior Vice President of Sales Europe	1.9yrs	데이터 없음	데이터 없음
Liu Meirong	Executive Director	1.1yrs	데이터 없음	데이터 없음
Liqiao Ma	Executive Director	less than a year	데이터 없음	0.0084% CN¥ 208.0k
Wai Chiu Wong	Company Secretary	3.1yrs	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 2500 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Liu Meirong	Executive Director	1.1yrs	데이터 없음	데이터 없음
Liqiao Ma	Executive Director	less than a year	데이터 없음	0.0084% CN¥ 208.0k
Martin B. Leon	Member of Advisory Board	no data	데이터 없음	데이터 없음
Chaim Lotan	Member of Global Advisory Board	4.1yrs	데이터 없음	데이터 없음
Ting Yuk Wu	Independent Non-Executive Director	5.3yrs	CN¥423.00k	데이터 없음
Chi Wai Suen	Independent Non-Executive Director	4.6yrs	CN¥335.00k	데이터 없음
Wei Wang	Shareholders Representative Supervisor	5.3yrs	데이터 없음	데이터 없음
Scott Lim	Member of Global Advisory Board	4.1yrs	데이터 없음	데이터 없음
Min Shao	Employee Representative Supervisor	1.5yrs	데이터 없음	데이터 없음
Zhang Ao	Non-Executive Director	1.1yrs	데이터 없음	데이터 없음
Yue Li	Shareholders Representative Supervisor	1.8yrs	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: 2500 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Venus Medtech (Hangzhou) 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

Consensus EPS estimates fall by 24%

No longer forecast to breakeven

First half 2023 earnings released: CN¥0.80 loss per share (vs CN¥0.46 loss in 1H 2022)

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

Forecast to breakeven in 2025

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

Consensus revenue estimates fall by 25%

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Forecast breakeven date pushed back to 2023

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

GM & Executive Director recently bought HK$35m worth of stock

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

GM & Executive Director recently bought HK$6.0m worth of stock

GM & Executive Director recently bought HK$30m worth of stock

Forecast breakeven pushed back to 2022

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

National Medical Products Administration of China Approves Venus Medtech's VenusA-Plus Transcatheter Prosthetic Aortic Valve Replacement System - Retrievable Delivery System